1
|
Yu E, Park S, Goh J, Shin S, Mehra N, McDermott R, Sala Gonzalez M, Fong P, Greil R, Retz M, Sade J, Huang YH, Begbie S, Rey F, Kramer G, Suzuki H, Zhang J, Kim J, Poehlein C, Antonarakis E. 1362MO Pembrolizumab + olaparib vs abiraterone (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC): Randomized open-label phase III KEYLYNK-010 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1494] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Grimison P, Mersiades A, Kirby A, Lintzeris N, Morton R, Haber P, Olver I, Walsh A, McGregor I, Cheung Y, Tognela A, Hahn C, Briscoe K, Aghmesheh M, Fox P, Abdi E, Clarke S, Della-Fiorentina S, Shannon J, Gedye C, Begbie S, Simes J, Stockler M. Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. Ann Oncol 2020; 31:1553-1560. [DOI: 10.1016/j.annonc.2020.07.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2020] [Revised: 07/14/2020] [Accepted: 07/27/2020] [Indexed: 10/23/2022] Open
|
3
|
Vasista A, Martin A, Pavlakis N, Sjoquist K, Snow S, Jonker D, Chua Y, Epstein R, Bonaventura A, Khasraw M, Varma S, Singhal N, Ransom D, Aubin F, Burkes R, Lim H, Lemay F, Begbie S, Stockler M, Kiely B. Accuracy and prognostic significance of oncologists’ estimates and scenarios for survival time in a randomised Phase 2 trial of regorafenib in advanced gastric cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
4
|
Davidson A, Veillard AS, Tognela A, Chan MMK, Hughes BGM, Boyer M, Briscoe K, Begbie S, Abdi E, Crombie C, Long J, Boyce A, Lewis CR, Varma S, Broad A, Muljadi N, Chinchen S, Espinoza D, Coskinas X, Pavlakis N, Millward M, Stockler MR. A phase III randomized trial of adding topical nitroglycerin to first-line chemotherapy for advanced nonsmall-cell lung cancer: the Australasian lung cancer trials group NITRO trial. Ann Oncol 2015; 26:2280-6. [PMID: 26347110 DOI: 10.1093/annonc/mdv373] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2015] [Accepted: 08/29/2015] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND We sought to determine whether the substantial benefits of topical nitroglycerin with first-line, platinum-based, doublet chemotherapy in advanced nonsmall-cell lung cancer (NSCLC) seen in a phase II trial could be corroborated in a rigorous, multicenter, phase III trial. PATIENTS AND METHODS Patients starting one of five, prespecified, platinum-based doublets as first-line chemotherapy for advanced NSCLC were randomly allocated treatment with or without nitroglycerin 25 mg patches for 2 days before, the day of, and 2 days after, each chemotherapy infusion. Progression-free survival (PFS) was the primary end point. RESULTS Accrual was stopped after the first interim analysis of 270 events. Chemotherapy was predominantly with carboplatin and gemcitabine (79%) or carboplatin and paclitaxel (18%). The final analysis included 345 events in 372 participants with a median follow-up of 33 months. Topical nitroglycerin had no demonstrable effect on PFS [median 5.0 versus 4.8 months, hazard ratio (HR) = 1.07, 95% confidence interval (CI) 0.86-1.32, P = 0.55], overall survival (median 11.0 versus 10.3 months, HR = 0.99, 95% CI 0.79-1.24, P = 0.94), or objective tumor response (31% versus 30%, relative risk = 1.03, 95% CI 0.82-1.29, P = 0.81). Headache, hypotension, syncope, diarrhea, dizziness, and anorexia were more frequent in those allocated nitroglycerin. CONCLUSION The addition of topical nitroglycerin to carboplatin-based, doublet chemotherapy in NSCLC had no demonstrable benefit and should not be used or pursued further. CLINICAL TRIALS NUMBER Australian New Zealand Clinical Trials Registry Number ACTRN12608000588392.
Collapse
Affiliation(s)
- A Davidson
- Department of Medical Oncology, Fiona Stanley Hospital, Perth
| | - A-S Veillard
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - A Tognela
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - M M K Chan
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - B G M Hughes
- Department of Medical Oncology, The Prince Charles Hospital, Brisbane School of Medicine, University of Queensland, Brisbane
| | - M Boyer
- Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown
| | - K Briscoe
- Department of Medical Oncology, Coffs Harbour Health Campus, Coffs Harbour
| | - S Begbie
- Department of Medical Oncology, Port Macquarie Base Hospital, Port Macquarie
| | - E Abdi
- Department of Medical Oncology, The Tweed Hospital, Tweed Heads School of Medicine & Dentistry, Griffith University, Southport
| | - C Crombie
- Department of Medical Oncology, Nepean Cancer Care Centre, Kingswood
| | - J Long
- Department of Medical Oncology, Nambour General Hospital, Nambour
| | - A Boyce
- Department of Medical Oncology, Lismore Base Hospital, Lismore
| | - C R Lewis
- Prince of Wales Hospital Clinical School, University of New South Wales, Randwick
| | - S Varma
- Department of Medical Oncology, The Townsville Hospital, Townsville
| | - A Broad
- Department of Medical Oncology, Geelong Hospital, Geelong
| | - N Muljadi
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - S Chinchen
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - D Espinoza
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - X Coskinas
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | - N Pavlakis
- Department of Medical Oncology, Royal North Shore Hospital, St Leonards
| | - M Millward
- Department of Medical Oncology, Sir Charles Gardiner Hospital, Nedlands School of Medicine and Pharmacology, University of Western Australia, Crawley, Australia
| | - M R Stockler
- NHMRC Clinical Trials Centre, University of Sydney, Sydney
| | | | | |
Collapse
|
5
|
Davidson A, Veillard A, Tognela A, Chan M, Briscoe K, Hughes B, Boyer M, Begbie S, Muljadi N, Coskinas X, Chinchen S, Millward M, Pavlakis N, Stockler M. A Phase 3 Randomised Trial of Adding Nitroglycerin to First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer: the Australasian Lung Cancer Trials Group Nitro Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.24] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
6
|
Ramalingam S, Crawford J, Chang A, Manegold C, Perez-Soler R, Douillard JY, Thatcher N, Barlesi F, Owonikoko T, Wang Y, Pultar P, Zhu J, Malik R, Giaccone G, Della-Fiorentina S, Begbie S, Jennens R, Dass J, Pittman K, Ivanova N, Koynova T, Petrov P, Tomova A, Tzekova V, Couture F, Hirsh V, Burkes R, Sangha R, Ambrus M, Janaskova T, Musil J, Novotny J, Zatloukal P, Jakesova J, Klenha K, Roubec J, Vanasek J, Fayette J, Barlesi F, Bennouna-Louridi J, Chouaid C, Mazières J, Vallerand H, Robinet G, Souquet PJ, Spaeth D, Schott R, Lena H, Martinet Y, El Kouri C, Baize N, Scherpereel A, Molinier O, Fuchs F, Josten K, Manegold C, Marschner N, Schneller F, Overbeck T, Thomas M, von Pawel J, Reck M, Schuette W, Hagen V, Schneider CP, Georgoulias V, Varthalitis I, Zarogoulidis K, Syrigos K, Papandreou C, Bocskei C, Csanky E, Juhasz E, Losonczy G, Mark Z, Molnar I, Papai-Szekely Z, Tehenes S, Vinkler I, Almel S, Bakshi A, Bondarde S, Maru A, Pathak A, Pedapenki R, Prasad K, Prasad S, Kilara N, Gorijavolu D, Deshmukh C, John S, Sharma L, Amoroso D, Bajetta E, Bidoli P, Bonetti A, De Marinis F, Maio M, Passalacqua R, Cascinu S, Bearz A, Bitina M, Brize A, Purkalne G, Skrodele M, Baba A, Ratnavelu K, Saw M, Samson-Fernando M, Ladrera G, Jassem J, Koralewski P, Serwatowski P, Krzakowski M, Cebotaru C, Filip D, Ganea-Motan D, Ianuli C, Manolescu I, Udrea A, Burdaeva O, Byakhov M, Filippov A, Lazarev S, Mosin I, Orlov S, Udovitsa D, Khorinko A, Protsenko S, Chang A, Lim H, Tan Y, Tan E, Bastus Piulats R, Garcia-Foncillas J, Valdivia J, de Castro J, Domine Gomez M, Kim S, Lee JS, Kim H, Lee J, Shin S, Kim DW, Kim YC, Park K, Chang CS, Chang GC, Goan YG, Su WC, Tsai CM, Kuo HP, Benekli M, Demir G, Gokmen E, Sevinc A, Crawford J, Giaccone G, Haigentz M, Owonikoko T, Agarwal M, Pandit S, Araujo R, Vrindavanam N, Bonomi P, Berg A, Wade J, Bloom R, Amin B, Camidge R, Hill D, Rarick M, Flynn P, Klein L, Lo Russo K, Neubauer M, Richards P, Ruxer R, Savin M, Weckstein D, Rosenberg R, Whittaker T, Richards D, Berry W, Ottensmeier C, Dangoor A, Steele N, Summers Y, Rankin E, Rowley K, Giridharan S, Kristeleit H, Humber C, Taylor P. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial). Ann Oncol 2013; 24:2875-80. [DOI: 10.1093/annonc/mdt371] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
7
|
Khasraw M, Pavlakis N, McCowatt S, Underhill C, Begbie S, de Souza P, Boyce A, Parnis F, Lim V, Harvie R, Marx G. Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol 2009; 21:1302-1307. [PMID: 19917571 DOI: 10.1093/annonc/mdp524] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Docetaxel (Taxotere) improve survival and prostate-specific antigen (PSA) response rates in patients with metastatic castrate-resistant prostate cancer (CRPC). We studied the combination of PI-88, an inhibitor of angiogenesis and heparanase activity, and docetaxel in chemotherapy-naive CRPC. PATIENTS AND METHODS We conducted a multicentre open-label phase I/II trial of PI-88 in combination with docetaxel. The primary end point was PSA response. Secondary end points included toxicity, radiologic response and overall survival. Doses of PI-88 were escalated to the maximum tolerated dose; whereas docetaxel was given at a fixed 75 mg/m(2) dose every three weeks RESULTS Twenty-one patients were enrolled in the dose-escalation component. A further 35 patients were randomly allocated to the study to evaluate the two schedules in phase II trial. The trial was stopped early by the Safety Data Review Board due to a higher-than-expected febrile neutropenia of 27%. In the pooled population, the PSA response (50% reduction) was 70%, median survival was 61 weeks (6-99 weeks) and 1-year survival was 71%. CONCLUSIONS The regimen of docetaxel and PI-88 is active in CRPC but associated with significant haematologic toxicity. Further evaluation of different scheduling and dosing of PI-88 and docetaxel may be warranted to optimise efficacy with a more manageable safety profile.
Collapse
Affiliation(s)
- M Khasraw
- Department of Oncology, Royal North Shore Hospital.
| | - N Pavlakis
- Department of Oncology, Royal North Shore Hospital
| | - S McCowatt
- Department of Oncology, Royal North Shore Hospital; Sydney New South Wales Haematology and Oncology Clinics, Sydney, New South Wales
| | | | - S Begbie
- Department of Oncology, Port Macquarie Base Hospital, Port Macquarie
| | - P de Souza
- UNSW, St George Hospital Clinical School, Sydney
| | - A Boyce
- Department of Oncology, Lismore Base Hospital, Lismore, New South Wales
| | - F Parnis
- Ashford Cancer Centre, Adelaide, South Australia, Australia
| | - V Lim
- Department of Oncology, Royal North Shore Hospital
| | - R Harvie
- Department of Oncology, Royal North Shore Hospital
| | - G Marx
- Department of Oncology, Royal North Shore Hospital; Sydney New South Wales Haematology and Oncology Clinics, Sydney, New South Wales
| |
Collapse
|
8
|
Kremser T, Evans A, Moore A, Luxford K, Begbie S, Bensoussan A, Marigliani R, Zorbas H. Use of complementary therapies by Australian women with breast cancer. Breast 2008; 17:387-94. [DOI: 10.1016/j.breast.2007.12.006] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2007] [Revised: 11/08/2007] [Accepted: 12/04/2007] [Indexed: 11/30/2022] Open
|
9
|
Marx GM, Pavlakis N, McCowatt S, Begbie S, Underhill C, Boyce A, Katelaris P. ProTat: A phase II trial of docetaxel (D), prednisolone (P) and thalidomide (T) in patients with androgen-independent prostate cancer (AIPC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.4672] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- G. M. Marx
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| | - N. Pavlakis
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| | - S. McCowatt
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| | - S. Begbie
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| | - C. Underhill
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| | - A. Boyce
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| | - P. Katelaris
- Sydney Hem/Onc Clinic, Sydney, NSW, Australia; Royal North Shore Hosp, Sydney, Australia; Port Macquarie Hosp, Port Macquarie, Australia; Border Medcl Oncology, Albury Wodonga, Australia; Lismore Base Hosp, Lismore, Australia; Sydney Adventist Hosp, Sydney, Australia
| |
Collapse
|
10
|
Scheithauer W, McKendrick J, Begbie S, Borner M, Burns WI, Burris HA, Cassidy J, Jodrell D, Koralewski P, Levine EL, Marschner N, Maroun J, Garcia-Alfonso P, Tujakowski J, Van Hazel G, Wong A, Zaluski J, Twelves C. Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Ann Oncol 2004; 14:1735-43. [PMID: 14630678 DOI: 10.1093/annonc/mdg500] [Citation(s) in RCA: 193] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
BACKGROUND Oral capecitabine achieves a superior response rate with an improved safety profile compared with bolus 5-fluorouracil-leucovorin (5-FU/LV) as first-line treatment for patients with metastatic colorectal cancer. We report here the results of a large phase III trial investigating adjuvant oral capecitabine compared with 5-FU/LV (Mayo Clinic regimen) in Dukes' C colon cancer. PATIENTS AND METHODS Patients aged 18-75 years with resected Dukes' C colon carcinoma were randomized to receive 24 weeks of treatment with either oral capecitabine 1250 mg/m(2) twice daily, days 1-14 every 21 days (n = 993), or i.v. bolus 5-FU 425 mg/m(2) with i.v. leucovorin 20 mg/m(2) on days 1-5, repeated every 28 days (n = 974). RESULTS Patients receiving capecitabine experienced significantly (P <0.001) less diarrhea, stomatitis, nausea/vomiting, alopecia and neutropenia, but more hand-foot syndrome than those receiving 5-FU/LV. Fewer patients receiving capecitabine experienced grade 3 or 4 neutropenia, febrile neutropenia/sepsis and stomatitis (P <0.001), although more experienced grade 3 hand-foot syndrome than those treated with 5-FU/LV (P <0.001). Capecitabine demonstrates a similar, favorable safety profile in patients aged <65 years or > or = 65 years old. CONCLUSIONS Based on its improved safety profile, capecitabine has the potential to replace 5-FU/LV as standard adjuvant treatment for patients with colon cancer. Efficacy results are expected to be available in Keywords: Adjuvant treatment, capecitabine, chemotherapy, colorectal cancer
Collapse
Affiliation(s)
- W Scheithauer
- Klinik für Innere Medizin I, Vienna University Medical School, Vienna, Austria.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
|
12
|
Abstract
A 47-year-old woman developed pulmonary eosinophilia from the use of maloprim as malaria prophylaxis. The diagnosis was confirmed by bronchoalveolar lavage (BAL) and transbronchial lung biopsy. Her condition improved with drug withdrawal and steroid therapy. With the increased use of pyrimethamine and dapsone in the treatment of human immunodeficiency syndrome (HIV) infection, this form of drug allergy may become more common.
Collapse
Affiliation(s)
- S Begbie
- Department of Internal Medicine, Manly Hospital, Sydney, NSW, Australia
| | | |
Collapse
|